Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acthar Gel for Severe Noninfectious Uveitis (NIPPU)
NCT03656692Phase 4Terminated
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Oct 2018
- Primary completion
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of repository corticotropin injection in non-infectious intermediate uveitis, posterior uveitis and panuveitis, sponsored by Mallinckrodt Pharmaceuticals. Primary endpoints: Score on the Nussenblatt Grading Scale at Week 36, Score on the Laser Flare Scale at Week 36 and 1 more. Started Oct 2018; status: terminated.
02
Drugs
repository corticotropin injection
03
Conditions
non-infectious intermediate uveitisposterior uveitispanuveitis
Beyond the preview
Go deeper on NCT03656692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03656692.